| Identification | Back Directory | [Name]
Birinapant | [CAS]
1629229-37-3 | [Synonyms]
ESN-364
FEZOLINETANT; ESN-364; ESN 364; ESN364
Methanone, [(8R)-5,6-dihydro-8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl](4-fluorophenyl)- | [Molecular Formula]
C16H15FN6OS | [MDL Number]
MFCD30532641 | [MOL File]
1629229-37-3.mol | [Molecular Weight]
358.39 |
| Chemical Properties | Back Directory | [Boiling point ]
623.0±65.0 °C(Predicted) | [density ]
1.56±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:20.0(Max Conc. mg/mL);55.8(Max Conc. mM) | [form ]
Solid | [pka]
-0.28±0.40(Predicted) | [color ]
White to yellow | [InChI]
InChI=1S/C16H15FN6OS/c1-9-13-19-20-14(15-18-10(2)21-25-15)23(13)8-7-22(9)16(24)11-3-5-12(17)6-4-11/h3-6,9H,7-8H2,1-2H3/t9-/m1/s1 | [InChIKey]
PPSNFPASKFYPMN-SECBINFHSA-N | [SMILES]
C(N1CCN2C(C3SN=C(C)N=3)=NN=C2[C@H]1C)(C1=CC=C(F)C=C1)=O |
| Hazard Information | Back Directory | [Uses]
Fezolinetant is an antagonist of the neurokinin 3 receptor (NK3R), used for the treatment of menopausal hot flushes. | [Definition]
ChEBI: Fezolinetant is a triazolopyrazine that is 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine substituted by 3-methyl-1,2,4-thiadiazol-5-yl, 4-fluorobenzoyl and methyl groups at positions 3, 7, and 8R, respectively. It is a prescription medicine used to reduce moderate to severe vasomotor symptoms due to menopause. It has a role as a neurokinin-3 receptor antagonist. It is a member of monofluorobenzenes, a triazolopyrazine, a member of thiadiazoles, a member of benzamides and a tertiary carboxamide. | [Mechanism of action]
Fezolinetant is an oral non-hormonal therapy that is an NK3R antagonist. It works by binding to and blocking the activity of NK3 receptors, which play a role in the regulation of body temperature in the brain. | [Side effects]
The common side effects of Fezolinetant include abdominal pain, diarrhoea, insomnia, back pain, hot flushes and elevated liver transaminases. |
|
|